Abstract
We investigated lymphoma risk following hepatitis infection in a case-control study of 274 incident lymphoma cases, defined according to the WHO classification, and 336 population controls in Sardinia, Italy. Part of our study population (198 cases and 219 controls) was included in the EPILYMPH study of Hepatitis C virus (HCV) infection in relation to non-Hodgklin’s lymphoma risk. Based on questionnaire information on whether and at what age a diagnosis of hepatitis was posed by a physician, systematic anti-HCV antibodies testing in cases and controls by enzyme-linked immunoassay, and HCV-RNA assessment by PCR analyses in positive samples, we investigated more in detail whether hepatitis non-C is also associated with lymphoma risk, and whether risk varies by clinical form of hepatitis (acute or chronic infection). After adjusting by age, gender, education, and area of birth whether from the study area or elsewhere in Italy, a previous generic diagnosis of hepatitis was associated with a significantly elevated lymphoma risk [odds ratio (OR) = 1.8; 95% CI 1.1, 2.8], which was equally increased for hepatitis B (OR = 1.8; 95% CI 0.9, 3.5), for HCV positive subjects overall (OR = 2.0; 95% CI 0.8, 4.8), and for hepatitis non-B non-C (OR = 1.6; 95% CI 0.7, 3.9). Once concurrent infection from other hepatitis viruses was excluded, acute or chronic hepatitis C was the only one showing a consistent risk increase in all lymphoma subtypes, but follicular lymphoma. Some indications of an excess risk of lymphoma were observed also for acute, but not chronic forms of hepatitis B and hepatitis non-B, non C. Self-limited hepatitis C did not show an association. No significant heterogeneity in the risk of major lymphoma subtype was observed. Our results confirm a role of either acute or chronic active HCV infection in lymphomagenesis. Further studies are warranted to test the hypothesis that acute infection from other hepatitis viruses might also increase lymphoma risk.
Similar content being viewed by others
References
Luppi M, Torelli G. The new lymphotropic herpes viruses (HHV-6, HHV-7, HHV-8) and hepatitis C virus (HCV) in human lymphoproliferative diseases: an overview. Haematologica. 1996;81:265–81.
Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin’s lymphoma: a meta-analysis of epidemiological studies. Cancer Sci. 2004;95:745–52.
Talamini R, Montella M, Crovatto M, et al. Non-Hodgkin’s lymphoma and hepatitis C virus: a case-control from northern and southern Italy. Int J Cancer. 2004;110:380–5.
Mele A, Pulsoni A, Elvira Bianco E, et al. Hepatitis C virus and B cell non-Hodgkin lymphomas: an Italian multi-centre case-control study. Blood. 2003;102:996–9.
Seve P, Renaudier P, Sasco AJ, et al. Hepatitis C virus infection and B cell non-Hodgkin’s lymphoma: a cross-sectional study in Lyon, France. Eur J Gastroenterol Hepatol. 2004;16:1361–5.
Cowgill KD, Loffredo CA, Eissa SA, et al. Case-control study of non-Hodgkin’s lymphoma and hepatitis C virus infection in Egypt. Int J Epidemiol. 2004;33:1034–9.
Takeshita M, Sakai H, Okamura S, et al. Prevalence of hepatitis C virus infection in cases of B cell lymphoma in Japan. Histopathology. 2006;48:189–98.
Morton LM, Engels EA, Holford TR, et al. Hepatitis C virus and risk of non-Hodgkin lymphoma: a population-based case-control study among Connecticut women. Cancer Epidemiol Biomarkers Prev. 2004;13:425–30.
De Sanjose S, Nieters A, Goedert JJ, et al. Role of Hepatitis C virus infection in malignant lymphoma in Spain. Int J Cancer. 2004;111:81–5.
Duberg AS, Nordstrom M, Torner A, et al. Non-Hodgkin’s lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology. 2005;41:652–9.
Crook PD, Jones ME, Hall AJ. Mortality of hepatitis B surface antigen-positive blood donors in England and Wales. Int J Epidemiol. 2003;32:118–24.
Nieters A, Kallinowski B, Brennan P, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology. 2006;131:1879–86.
Isikdogan A, Ayyildiz O, Dursun M, Tiftik N, Batun S, Muftuoglu E. Hepatitis C virus in patients with non-Hodgkin’s lymphoma in southeastern Anatolia region of Turkey: a prospective case-control study of 119 patients. Leuk Lymphoma. 2003;44:1745–7.
Salem Z, Nuwaiyri-Salti N, Ramlawi F, Ramia S. Hepatitis C virus infection in Lebanese patients with B cell non-Hodgkin’s lymphoma. Eur J Epidemiol. 2003;18:251–3.
Aviles A, Valdez L, Halabe J, et al. No association between lymphoma and hepatitis C virus. Med Oncol. 2003;20:165–8.
Engels EA, Chatterjee N, Cerhan JR, et al. Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study. Int J Cancer. 2004;111:76–80.
Franceschi S, Polesel J, Rickenbach M, et al. Hepatitis C virus and non-Hodgkin’s lymphoma: findings from the Swiss HIV cohort Study. Br J Cancer. 2006;95:1598–602.
Negri E, Little D, Boiocchi M, et al. B cell non-Hodgkin’s lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer. 2004;111:1–8.
Turner NC, Dusheiko G, Jones A. Hepatitis C and B cell lymphoma. Ann Oncol. 2003;14:1341–5.
Waters L, Stebbing J, Mandalia S, et al. Hepatitis C infection is not associated with systemic HIV-associated non-Hodgkin’s lymphoma: a cohort study. Int J Cancer. 2005;116:161–3.
Mazzaro C, Tirelli U, Pozzato G. Hepatitis C virus and non-Hodgkin’s lymphoma 10 years later. Dig Liver Dis. 2005;37:219–26.
Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. J Clin Oncol. 2005;23:468–73.
Armor JF, Fazili J, Toubia N, Kern W, Kamble R, Kharfan-Dabaja MA. Remission of natural-killer cell lymphoma of the liver with anti-hepatitis C therapy. Am J Hematol. 2005;78:212–5.
Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther. 2005;21:653–62.
Mazzaro C, Spina M, Tirelli U. Regression of low-grade non-Hodgkin’s lymphoma after treatment with pegylated interferon plus ribavirin in hepatitis C virus infection. J Clin Oncol. 2005;23:4470–1.
Kelaidi C, Rollot F, Park S, et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia. 2004;18:1711–6.
Svoboda J, Andreadis C, Downs LH, Miller WT Jr, Tsai DE, Schuster SJ. Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection. Leuk Lymphoma. 2005;46:1365–8.
Wu H, Zhu K, Levin LI, et al. Self-reported hepatitis and non-Hodgkin lymphoma: an analysis according to the time since hepatitis diagnosis. Ann Epidemiol. 2006;16:400–5.
Marcucci F, Mele A, Spada E, et al. High prevalence of hepatitis B virus infection in B cell non-Hodgkin’s lymphoma. Haematologica. 2006;91:554–7.
Ulcickas Yood M, Quesenberry CP Jr, Guo D, et al. Incidence of non-Hodgkin’s lymphoma among individuals with chronic hepatitis B virus infection. Hepatology. 2007;46:107–12.
Kuniyoshi M, Nakamuta M, Sakai H, et al. Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin’s lymphoma. J Gastroenterol Hepatol. 2001;16:215–9.
Wang F, Xu RH, Han B, et al. High incidence of hepatitis B virus infection in B cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer. 2007;109:1360–4.
Loviselli A, Oppo A, Velluzzi F, et al. Independent expression of serological markers of thyroid autoimmunity and hepatitis C infection in the general population: results of a community-based study in north-western Sardinia. J Endocrinol Invest. 1999;22:660–5.
Mele A, Mariano A, Tosti ME, et al. Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign. Clin Infect Dis. 2007;44:e17–24.
Vulcano A, Angelucci M, Candelori E, et al. HEV prevalence in the general population and among workers at zoonotic risk in Latium Region. Ann Ig. 2007;19:181–6.
Gessoni G, Manoni F. Hepatitis E virus infection in north–east Italy: serological study in the open population and groups at risk. Viral Hepat. 1996;3:197–202.
Besson H, Brennan P, Becker N, et al. Tobacco smoking, alcohol drinking and Hodgkin’s lymphoma: an European multi-centre case-control study (Epilymph). Br J Cancer. 2006;95:378–84.
Silvestri F, Barillari G, Fanin R, et al. Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma. Ann Oncol. 1998;9:499–504.
Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer. 2004;100:107–15.
Ivanovski M, Silvestri F, Pozzato G, et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood. 1998;91:2433–42.
Quinn ER, Chan CH, Hadlock KG, Foung SK, Flint M, Levy S. The B cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin’s lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood. 2001;98:3745–9.
Gisbert JP, Garcia-Buey L, Pajares JM, Moreno Otero R. Prevalence of hepatitis C virus infection in B cell non Hodgkin’s lymphoma: systematic review and meta-analysis. Gastroenterology. 2003;125:1723–32.
Acknowledgments
This paper was supported with funding from the Italian Ministry of Education, University and Scientific Research (PRIN 2001, prot. 2001067845), and the Compagnia di San Paolo (Programma Oncologia 2001). The authors conducted the work independent from study sponsors, who neither participated nor influenced the study design, data collection, analysis and interpretation, and writing of the report.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Cocco, P., Piras, G., Monne, M. et al. Risk of malignant lymphoma following viral hepatitis infection. Int J Hematol 87, 474–483 (2008). https://doi.org/10.1007/s12185-008-0086-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-008-0086-3